NASDAQ: CVCapsovision Inc Stock
$4.69-0.38 (-7.5%)
Updated Feb 10, 2026
CV Price
$4.69
Fair Value Price
N/A
Market Cap
$219.69M
52 Week Low
$3.45
52 Week High
$15.37
P/E
N/A
P/B
10.75x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.26
Operating Cash Flow
N/A
Beta
1.63
Next Earnings
Mar 31, 2026
Ex-Dividend
N/A
Next Dividend
N/A
CV Overview
Medical‑technology company developing advanced capsule endoscopy systems (CapsoCam Plus, CapsoCam Colon) and AI-enabled imaging platforms for gastrointestinal diagnostics
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CV's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
CV
Ranked#74 of 101
Ranked#74 of 101
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $27.67 | A | |
| $8.07 | A | |
| $88.72 | A |
Be the first to know about important CV news, forecast changes, insider trades & much more!
CV News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CV is poor value based on its book value relative to its share price (10.75x), compared to the US Medical Devices industry average (3.69x)
P/B vs Industry Valuation
CV's short-term assets ($24.05M) exceed its short-term liabilities ($4.64M)
Short-term Liabilities Financials
CV's short-term assets ($24.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more CV due diligence checks available for Premium users.
Valuation
CV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.75x
Industry
3.69x
CV is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CV's financial health
Profit margin
Revenue
$3.5M
Net Income
-$7.9M
Profit Margin
-223.9%
Assets to liabilities
Assets
$25.7M
Liabilities
$5.2M
Debt to equity
0.26
CV's short-term assets ($24.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CV's short-term assets ($24.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.7M
Investing
-$12.0k
Financing
$22.4M
CV vs Medical Device Stocks
Capsovision Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.